International Journal of Medical & Pharmaceutical Sciences (IJMPS)

IJMPS - 12(12), December, 2022

Pages: 01-09

Revisiting the Most Successful United States Food and Drug Administration-approved Anti-obesity Drug Sibutramine sulfate: A Comprehensive Pharmacotherapeutic Review

Author: Yadav L, Sahu S, Agrawal B, Meshram R

Category: Pharmaceutical Sciences

[Download PDF]

Abstract:

Introduction: Serotonin (5-HT) and noradrenaline (NA) reuptake inhibitor sibutramine work together. Sibutramine primarily affects food intake and energy expenditure by way of its two pharmacologically active metabolites, primary and secondary amines, which cause significant weight loss. In addition to stimulating thermogenesis and enhancing the physiological process of satiety, it can also increase the efferent sympathetic activity to brown fat that is thermochemically active. Aim: Revisiting the Most Successful United States Food and Drug Administration-approved Anti-obesity Drug Sibutramine sulfate. Methodology: For a duration of 10 years, literature is covered. Results: Clinical studies using sibutramine show a dose-related decrease in body weight, with weight loss up to 11% below the baseline that can last up to 18 months with ongoing therapy. Patients assigned to the sibutramine medication continued to lose weight throughout a 1-year period, reaching 15% below baseline, while the patients receiving the placebo treatment had some weight increase when weight loss is induced with a very low-calorie diet (VLCDL). By lowering the biochemical risk factors for obesity, such as plasma triglycerides, total cholesterol, low-density lipoprotein (LDL) cholesterol, glucose, and insulin, and raising HDL cholesterol, sibutramine enhances metabolic fitness. Conclusion: Sibutramine has been shown to be a beneficial treatment for obese people with moderately high blood pressure, and it has even been shown to reduce blood pressure on average as a result of weight reduction. The potential for misuse that is associated with amphetamine is not present with sibutramine, and in investigations evaluating abuse potential, it is identical to placebo.

Keywords: Anti-obesity drugs, Metabolic fitness, Obesity, Obesity-related disorders, Sibutramine, Pharmacotherapeutics

References:

1. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. World Health Organization: Geneva, 1998.

2. Pi-Sunyer FX. Medical hazards of obesity. Ann Int Med 1993; 119: 655–660.

3. Wickelgren I. Obesity: how big a problem? Science 1998; 280: 1364–1357.

4. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking US white women aged 40–64 years. Am J Epid 1995; 141: 1128–1141.

5. Hill JO, Peters JC. Environmental contributions to the obesity epidemic. Science 1998; 280: 1371–1374.

6. Woods SC, Seeley RJ, Porte Jr D, Schwartz MW. Signals that regulate food intake and energy homeostasis. Science 1008; 280: 1378–1383.

7. Blackburn L, Miller D, Chan S. Pharmaceutical treatment of obesity. Nurs Clin North Am 1997; 32: 831–848.

8. Heal D, Aspley S, Prow MR, Jackson HC, Martin K, Cheetham SC. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from D-Amphetamine D-Fenfluramine Int J Obesity 1998; 22 (1): S18–S28.

9. Cheetham SC, Viggers JA, Slater NA, Heal DJ, Buckett WR. [3H]Paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments. Neuropharmacol 1993; 32: 737–743.

10. Cheetham SC, Viggers JA, Butler SA, Prow MR, Heal DJ. [3H]Nisoxetine – a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect od DSP-4 lesioning and antidepressant treatments. Neuropharmacol 1996; 35: 63–70.

11. Heal DJ, Cheetam SC, Prow MR, Martin KF, Buckett WR. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br J Pharmacol 1998; 125: 301–308.

12. Heal DJ, Frankland AT, Gosden J, Hutchins LJ, Prow MR, Luscombe GP, Buckett WR. A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine. Psychopharmacol 1992; 107: 303–309.

13. Carruba MO, Picotti GB, Zambotti F, Mantegazza P. Effects of mazindol, fenfluramine and chlorimipramine on the 5-hydroxytryptamine uptake and storage mechanism in rat brain: similarities and differences. Naunyn Schmiedeberg’s Arch Pharmacol 1977; 300: 227–232.

14. Carruba MO, Picotti GB, Zambotti F, Mantegazza P. Mazindol and amphetamine as inhibitors of the uptake and releasers of [3H] dopamine by rat striatal synaptosomes. Naunyn Schmiedeberg’s Arch Pharmacol 1977; 298: 1–5.

15. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent Int J Obesity 1997; 21 (1): S25–S29.

16. Buckett WR, Thomas PC, Luscombe GP. The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down–regulation. Prog Neuropsychopharmacol Biol Psych 1988; 12: 575–584.

17. Gundlah C, Martin KF, Heal DJ, Auerbach SB. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther 1997; 283: 581–591.

18. Fantino M. Decrease of food intake and weight loss induced by sibutramine in the rat. Obesity Res 1995; 3 (4): 1995.

19. Stricker-Krongrad A, Burlet C, Souquet AM, Courcier A. Sibutramine effects on feeding behaviour: a dose-dependence and microstructural analysis Obesity Res 1995; 3 (4): 631S.

20. Stricker-Krongrad A, Souquet AM, Burlet C. Effects of sibutramine on feeding behaviour in obese and lean Zucker rats. Int J Obesity 1995; 19 (2): P399.

21. Stricker-Krongrad A, Souquet AM, Burlet C. Effects of sibutramine on feeding behaviour in dietary-induced obesity: a role of dietary components Int J Obesity 1995; 19 (2): P398.

22. Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS. Sibutramine reduces food intake in non-dieting women with obesity. Obesity Res 1998; 6: 1–11.

23. Halford JCG, Wanninayake SC, Blundell JE. Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 1998; 61: 159–168.

24. Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal D. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997; 121: 1613–1618.

25. Stricker-Krongrad A, Souquet AM, Jackson HC, Burlet C. Effect of various monoamine receptor antagonists on the decrease in food intake induced by sibutramine in the rat. Br J Pharmacol 1996; 117: 167P.

26. Zambotti F, Carruba MO, Barzaghi F, Vicentini L, Groppetti A, Mantegazza P. Behavioural effects of a new nonphenylethylamine anorexigenic agent: mazindol. Eur J Pharmacol 1976; 36: 405– 412.

27. Carruba MO, Coen E, Pizzi M, Memorandum M, Missale C, Spano PF, Mantegazza P. Mechanism of action of anorectic drugs: an overview. In: Carruba MO, Blundell JE (eds). Pharmacology of Eating Disorders: Theoretical and Clinical Developments. Raven Press: New York, 1986, pp 1–27.

28. Grignaschi G, Fanelli E, Scagnol I, Samanin R. Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats. Br J Pharmacol 1999; 127: 1190–1194.

29. Kennett GA, Curzon G. Potencies of antagonists indicate that 5-HT1C receptors mediate 1–3 (chlorophenyl) piperazineinduced hypophagia. Br J Pharmacol 1991; 103: 2016–2020.

30. Luscombe GP, Hopcroft RH, Thomas PC, Buckett WR. The contribution of metabolites to the rapid and potent downregulation of rat cortical b-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacol 1989; 28: 129–134.

31. Ungerstedt U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol Scand 1971; 367 (1): 49–67.

32. Carruba MO, Zambotti F, Vicentini L, Picotti GB, Mantegazza P. Pharmacology and biochemical profile of a new anorectic drug: mazindol. In: Garattini S, Samanin R (eds). Central Mechanisms of Anorectic Drugs. Raven Press: New York, 1978, pp 145–164.

33. Keller HH, Schaffner R, Carruba MO, Burckard WP, Pieri M, Bonetti EP, Scherschlicht R, Da Prada M, Haefely WE. Diclofensine (Ro 8–4650) – A potent inhibitor of monoamine uptake: biochemical and behavioural effects in comparison with nomifensine. In: Costa E, Racagni G (eds). Typical and Atypical Antidepressants: Molecular Mechanisms. Raven Press: New York, 1982, pp 249–263.

34. Di Chiara G, Acquas E, Tanda G, Cadoni C. Drugs of abuse: biochemical surrogates of specific aspects of natural reward? Bioch Soc Symp 1993; 59: 65–81.

35. Foltin RW, Fischman MW. Assessment of the abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend 1991; 28: 3–48.

36. Cole JO, Levin A, Beake B, Kaiser P, Scheinbaum ML. Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Psychopharmacol 1998; 18: 231–236.

37. Schuh LM, Schuster CR, Hopper JA, Mendel CM. Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacol 2000; 147: 339–346.

38. Connoley IP, Liu YL, Frost I, Reckless IP, Heal DJ, Stock MJ. Thermogenic effect of sibutramine and its metabolites. Br J Pharmacol 1999; 126: 1487–1495.

39. Danforth E Jr. Sibutramine and thermogenesis in humans. Int J Obesity 1999; 23: 1007–1008.

40. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998; 68: 1180–1186. 

41. Walsh KM, Leen E, Lean MEJ. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obesity 1999; 23: 1009– 1015.

42. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obesity 1999; 23: 1016–1024.

43. Liu Y-L, Kashani SMZ, Heal DJ, Stock MJ. Effect of sibutramine on tissue glucose utilization in the rat. Br J Pharmacol 1996; 117: 324P.

44. Trayhurn P. Brown adipose tissue and energy balance. In: Trayhurn P, Nicholls DG (eds). Brown Adipose Tissue. Edward Arnold: London, 1986, pp 52–85.

45. Himms-Hagen J. Brown adipose tissue and cold-acclimation. In: Trayhurn P, Nicholls DG (eds). Brown Adipose Tissue. Edward Arnold: London, 1986, pp 214–268.

46. Lean MEJ. Brown adipose tissue in humans. Proc Nutr Soc 1989; 48: 243–256.

47. Himms-Hagen J. Brown adipose tissue thermogenesis. FASEB J 1990; 4: 2890–2898.

48. Ricquier D, Bouillaud F. The brown adipose tissue mitocho drial uncoupling protein. In: Trayhurn P, Nicholls DG (eds). Brown Adipose Tissue. Edward Arnold: London, 1986, pp 86–104.

49. Himms-Hagen J, Desautels M. A mitochondrial defect in brown adipose tissue of obese (ob/ob) mouse: reduced binding of purine nucleotides and a failure to respond to cold by an increase in binding. Biochem Biophys Res Commun 1978; 83: 628–632.

50. Nisoli E, Briscini L, Tonello C, De-Giuli Morghen C, Carruba MO. Tumor necrosis factor-a induces apoptosis in rat brown adipocytes. Cell Death Diff 1997; 4: 771–778.

51. Hotamisligil GS, Shergill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-a: direct role in obesitylinked insulin resistance. Science 1993; 259: 87–91.

52. Nisoli E, Briscini L, Giordano A, Tonello C, Weisbrock SM, Uysal KT, Cinti S, Carruba MO, Hotamisligil GS. Tumor necrosis factor-a mediates apoptosis of brown adipocytes and defective brown adipocyte function in obesity. Proc Natl Acad Sci USA 2000; 97: 8033–8038.

53. McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998; 56: 1093–1124.

54. American Association of Clinical Endocrinologists (AACE)/ American College of Endocrinology (ACE). Obesity statement. Endocr Pract 1997; 3: 165–208.

55. Shape Up America! and the American Obesity Association. Guidance for treatment of adult obesity. American Obesity Association: Chicago, 1996.

56. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996; 276: 1907–1915.

57. Kaiser PE, Hinson JL. Sibutramine: dose response and plasma metabolite concentrations in weight loss. J Clin Pharmacol 1994; 34: 1019.

58. Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther 1991; 50: 330–337.

59. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB. Sibutramine produces dose-related weight loss. Obesity Res 1999; 7: 189–198.

60. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese patients: a doseranging study. Int J Obesity 1998; 22: 32–38.

61. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a verylow-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106: 179–184.

62. Kelly F, Wade AG, Jones SP, Johnson SG. Sibutramine hydrochloride vs dexfenfluramine: weight loss in obese subjects. Int J Obesity (Suppl )2 1994; 18: 61.

63. Drouin P, Hanotin C, Thomas F. Efficacy and tolerability of sibutramine versus dexfenfluramine in obese patients. Int J Obesity (Suppl )2 1995; 19: 144.

64. Lean MEJ, Campbell S, Walsh K. Sibutramine in the treatment of obese patients with dyslipidaemia. Int J Obesity 1998; 22 (3): 270.

65. Fitchet M, Shepherd G, Kelly F. Sibutramine: a meta-analysis of changes in fasting serum lipids in placebo controlled Studies. Int J Obesity 1997; 21 (2): 53.

66. Federal Drug Administration New Drug Approval package. (1998). Study number SB2059. [WWW document] URL http// www.fda.gov.cder/foi/nda/index97.html

67. Lean MEJ. Sibutramine -a review of clinical efficacy. Int J Obesity 1997; 21: S30–S36.

68. Griffiths J, Brynes AE, Frost G, Bloom SR, Finer N, Jones SP, Romanec FM. Sibutramine in the treatment of overweight noninsulin-dependent diabetics. Int J Obesity 1995; 19 (2): 41.

69. Fujioka K, Weinstein SP, Rowe E. Sibutramine induces weight loss and improves glycemic control in obese patients with type 2 diabetes mellitus. Diabetologia 1998; 41 (1): 215.

70. Vargas R, McMahon FG, Jain AK. Effects of sibutramine vs. placebo in NIDDM. 95th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. 1994, pp 188.

71. Van Gaal LF, De Wauters MA, Leew IH. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment Exp Clin Endocrinol Diabetes 1998; 106 (2): 35–40.

72. Hazenberg BP, Johnson SG, Kelly F. Sibutramine in the treatment of obese subjects with hypertension. Int J Obesity 1998; 20 (4): 156.

73. Bach DS, Rissanen AM, Mendel CM, Shepherd G, Weinstein SP, Kelly F, Seaton TB, Patel B, Pekkarinen TA, Armstrong WF. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obesity Res 1999; 7: 363–369.

74. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW. Possible role of valvular serotonin 5-HT (2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000; 57: 75–81.